Comment on CMS-2026-1256-0002
Gilead SciencesOpposeBusiness
Summary: Gilead Sciences, Inc. opposes proposed changes that would limit opportunities for innovative technologies to apply for New Technology Add-on Payments (NTAP), arguing these changes could create barriers to patient access. The company also advocates for more transparent and consistent MS-DRG assignment methodologies for CAR T-cell and other immunotherapies to ensure stable hospital reimbursement.
Please see the attached comment letter from Gilead Sciences on the FY2027 Inpatient Prospective Payment System proposed rule. Thank you.